66.7% of cases had mutations in genes of the JAK-STAT signaling pathway which was known as a major oncogenic mechanism in T cell lymphomas, including STAT5B mutations (4/9), JAK3 mutations (3/9), and STAT5A mutations (2/9) (Fig. 3 C). The gene discussed is STAT5A; the disease is T-cell non-Hodgkin lymphoma.